Home > Dermatology > SPIN 2022 > Psoriasis: The Beat Goes On > GPP flares: pronounced undertreatment is common

GPP flares: pronounced undertreatment is common

Presented By
Dr Wendell Valdecantos , Boehringer Ingelheim Pharmaceuticals, CT, USA
SPIN 2022
According to a US retrospective analysis of healthcare records from 2015 to 2020, a quarter of patients with general pustular psoriasis (GPP) flares receive no treatment at all. Despite severe and potentially life-threatening symptoms, many patients were only treated with pain medication and topical steroids. Due to the rareness and unpredictability of GPP flares, only minimal research documenting the characteristics of these events has been performed. “Therefore, our study aimed to characterise flare episodes in GPP patients and respective treatments,” said Dr Wendell Valdecantos (Boehringer Ingelheim Pharmaceuticals, CT, USA), who presented the study [1]. This retrospective descriptive study included adult patients with GPP (ICD-10 code L40.1) identified in US electronic health record (EHR) data between 1 July 2015 and 30 June 2020. Only patients with at least 12 months of healthcare activity documented in the EHR after the GPP diagnosis and with ...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on